Cure of an established nonimmunogenic tumor, SCC VII, with a novel interleukin 12-based immunotherapy regimen in C3H mice

Archives of Otolaryngology - Head and Neck Surgery

Volumn 129, Issue 7, 2003, Pages 786-792

  Mandpe, Aditi H ^a,c   Tsung, Kangla ^b,c   Norton, Jeffrey A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 12; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER REGRESSION; CONTROLLED STUDY; DRUG EFFECT; HEAD CANCER; IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INCUBATION TIME; MOUSE; NECK CANCER; NONHUMAN; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; CARCINOMA, SQUAMOUS CELL; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERLEUKIN-12; MICE; MICE, INBRED C3H; MODELS, ANIMAL; PROSPECTIVE STUDIES;

EID: 0037489569     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.129.7.786     Document Type: Article

References (26)

1. Berlinger NT, Hilal EY, Oettgen HT, Good RA. Deficient cell-mediated immunity in head and neck cancer patients secondary to autologous suppressive immune cells. Laryngoscope. 1978;88:470-483.
2. Kessler DJ, Mickel RA, Lichtenstein A. Depressed natural killer cell activity in cervical lymph nodes containing focal metastatic squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1988;114:313-318.
3. Lang S, Whiteside TL, Lebeau A, Zeidler R, Mack B, Wollenberg B. Impairment of T-cell activation in head and neck cancer in situ and in vitro. Arch Otolaryngol Head Neck Surg. 1999;125:82-88.
4. Mickel RA, Kessler DJ, Taylor JMG, Lichtenstein A. Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients. Cancer Res. 1988;48:5017-5022.
5. Schantz SP, Shillitoe EJ, Brown B, Campbell B. Natural killer cell activity and head and neck cancer: a clinical assessment. J Natl Cancer Inst. 1986;77:869-875.
6. Wanebo HJ, Jun MY, Strong EW, Oettgen H. T-cell deficiency in patients with squamous cell carcinoma of the head and neck. Am J Surg. 1975;130:445-451.
7. Wang MB, Lichtenstein A, Mickel RA. Hierarchical immunosuppression of re gional lymph nodes in patients with head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 1991;105:517-527.
8. Whiteside TL, Letessier E, Hirabayashi H, et al. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res. 1993; 53:5654-5662.
9. Cortesina G, DeStefani A, Galeazzi E, et al. The effect of preoperative local interleukin-2 (IL-2) injections in patients with head and neck squamous cell carcinoma. Acta Ototaryngol. 1991;111:428-433.
10. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223-1240.
11. Nastala CL, Edington HD, McKinney TG, et al. Recombinant interleukin-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994;153:1697-1706.
12. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12. J Immunol. 1995;155:1393-1403.
13. Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA. Interleukin-12 induces T helper 1-directed antitumor response. J Immunol. 1997;158:3359-3365.
14. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol. 1991;146:3074-3081.
15. + T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA. 1993;90:10188-10192.
16. Trinchieri G. Interleukin-12 and its role in the generation of T cells. Immunol Today. 1993;14:335-338.
17. Mitsuoka A, Baba M, Morikawa S. Enhancement of delayed hypersensitivity by depletion of suppressor T cells with cyclophosphamide in mice. Nature. 1976; 262:77-78.
18. Tsung K, Meko JB, Tsung YL, Peplinski GR, Norton JA. Immune response against large tumor eradicated by treatment with cyclophosphamide and interleukin-12. J Immunol. 1998;160:1369-1377.
19. Le HN, Lee NC, Tsung K, Norton JA. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. J Immunol. 2001;167:6765-6772.
20. O'Malley BW, Cope KA, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg. 1997; 123:20-24.
21. Khurana D, Martin EA, Kasperbauer JL, et al. Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy. Head Neck. 2001;23:899-906.
22. Meyers JN, Mank-Seymour A, Zitvogel L, et al. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope. 1998;108:261-268.
23. North RJ, Kirstein DP. T-cell mediated concomitant immunity to syngeneic tumors, I: activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites. J Exp Med. 1977;145:275-292.
24. Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4 suppressor T-cells. Cancer Res. 1989;49:1649-1654.
25. Awwad M, North RJ. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumor: evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cell rather than by reducing tumor burden. Immunology. 1988;65:87-92.
26. Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res. 2002;62: 5069-5075.